Hostname: page-component-77c89778f8-vsgnj Total loading time: 0 Render date: 2024-07-19T02:10:28.289Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparison of the Efficacy and Tolerability of Controlled-Release Carbamazepine with Conventional Carbamazepine

Published online by Cambridge University Press:  18 September 2015

Z. Dhalla ,
J. Bruni  and
J. Sutton
Z. Dhalla
Affiliation:
Division of Neurology, Wellesley Hospital and the University of Toronto, Toronto and the Tegretol CR® Study Group
J. Bruni*
Affiliation:
Division of Neurology, Wellesley Hospital and the University of Toronto, Toronto and the Tegretol CR® Study Group
J. Sutton
Affiliation:
Division of Neurology, Wellesley Hospital and the University of Toronto, Toronto and the Tegretol CR® Study Group
*
Suite 318, Jones Building, The Wellesley Hospital, 160 Wellesley Street E., Toronto, Ontario, Canada M4Y 1J3
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We compared the efficacy and tolerability of controlled-release carbamazepine (CBZ-CR) with conventional carbamazepine (CBZ) in 131 epileptic patients (both men and women, ages 6-65 years) in an open, multicentre, cross-over trial. Patients entered into the trial were previously on CBZ monotherapy or polytherapy. During the first 4 weeks, patients were treated with equivalent daily doses of CBZ and then switched to CBZ-CR for the subsequent 4 weeks. The majority of patients were switched to the more convenient b.i.d. dosing schedule of the controlled-release (CR) preparation without a detrimental effect on seizure frequency or adverse effects. In 44/131 (34%) of patients, the switch to CBZ-CR was accompanied by an improvement in tolerability, primarily due to a reduction in peak-dependent CNS side-effects such as tiredness, double or blurred vision, dizziness and ataxia. At the end of the study, investigators preferred CBZ-CR for 76% of their patients and 70% of the patients preferred CBZ-CR.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue 1 , February 1991 , pp. 66 - 68
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

1.Eichelbaum, M, Ekbom, J, Bertilsson, L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975; 8: 337–41.CrossRefGoogle ScholarPubMed
2.Eichelbaum, M, Bertilsson, L, Rane, A, et al. Autoinduction of carbamazepine metabolism in man. In: Anticonvulsant Drugs and Enzyme Induction. Richens, A, Woodford, B, eds. Amsterdam: Associated Scientific Publishers 1976; 147–158.Google Scholar
3.Macphee, GJA, Butler, E, Bordi, MJ.Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: A consequence of autoinduction of metabolism. Epilepsia 1987; 28 (3): 286–294.CrossRefGoogle ScholarPubMed
4.Paxton, JW, Aman, MG, Wery, JS. Fluctuations in salivary carbamazepine and carbamazepine-10, 11-epoxide concentration during the day in epileptic children. Epilepsia 1983; 24: 716–724.CrossRefGoogle Scholar
5.Hoppener, RJ, Juyer, A, Meijer, JWA, et al. Correlations between daily fluctuations of carbamazepine serum levels and intermittent side-effects. Epilepsia 1980; 21: 341–50.Google ScholarPubMed
6.Tomson, T.Interdosage fluctuations in plasma carbamazepine concentrations determine intermittent side-effects. Arch Neurol 1984; 41: 830–4.CrossRefGoogle ScholarPubMed
7.Gillham, RA, Williams, N, Weidman, K, et al. Concentration-effect relationship with carbamazepine and its epoxide on psychomotor and cognitive function. J Neurol, Neurosurg, Psychiatry 1988; 51: 929–933.CrossRefGoogle ScholarPubMed
8.Riva, R, Albani, F, Ambroselto, G, et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlations with intermittent side-effects. Epilepsia 1984; 25: 476–481.CrossRefGoogle ScholarPubMed
9.Riva, R, Contin, M, Albani, F, et al. Free and total plasma concentrations of carbamazepine and carbamazepine-10, 11-epoxide in epileptic patients: Diurnal fluctuations and relationship with side-effects. Ther Drug Monit 1984; 6: 408–13.CrossRefGoogle ScholarPubMed
10.Canger, R, et al. Conventional versus controlled-release carbamazepine: A multicentre, double-blind cross-over study. Boll Lega Ital Epilepsia (I) 1988; 62/63: 419–421.Google Scholar
11.Stoll, KD, Kraemer, G, Berger, A.Tegretol 400 retard in epilepsy: results of a multicentre study with 473 patients. In: Carbamazepin in der Neurologie. Symp Mainz, Jan 1987. Hsrg, V, Kraemer, VG, und Hopf-Stuttgart, HC eds. New York: Thieme 1987: 259–266.Google Scholar
12.Stenzel, E.ICarbamazepine slow-release in the treatment of epilepsy report on clinical experience. Akt Neurol (D) 1987; 14 (4): 127–131.CrossRefGoogle Scholar
13.Kraemer, G, Stol, KD.Tegretol 400 retard in Trigeminal Neuralgia: results of a multicentre study with 93 patients. In: Carbamazepin in der Neurologie. Symp., Mainz, Jan 1987. Hsrg, V, Kraemer, VG, und Hopf-Stuttgart, HC eds. New York: Thieme 1987: 267–271.Google Scholar
14.Stefan, H, Schaefer, H, Kuhnen, C.Clinical monitoring during carbamazepine slow-release, once-daily monotherapy. Epilepsia 1988; 29: 571–577.CrossRefGoogle ScholarPubMed
15.Blankenhorn, V, Buelau, P, Kraemer, G, et al. Tegretol 400 retard versus Tegretol 200 in the treatment of severe partial-epilepsy. A 1-year study. In: Carbamazepin in der Neurologie. Symp., Mainz, Jan. 1987. Hsrg, V, Kraemer, VG, und Hopf-Stuttgart, HC, eds. New York: Thieme 1987: 254–258.Google Scholar
16.Haas, S, Besser, R, Hoffman, F, et al. Clinical results on changing from Tegretol 200 to Tegretol 400 retard. In: Carbamazepin in der Neurologie. Symp., Mainz, Jan. 1987. Hsrg, V, Kraemer, VG, und Hopf-Stuttgart, HC, eds. New York: Thieme 1987: 246–248.Google Scholar
17.Besser, R, Kraemer, G, Katzmann, K, et al. Tegretol 400 retard steady-state kinetics in hospitalized and ambulatory patients. In: Carbamazepin in der Neurologie. Symp., Mainz, Jan. 1987. Hsrg, V, Kraemer, VG, und Hopf-Stuttgart, HC, eds. New York: Thieme 1987: 225–230.Google Scholar
18.Von Albert, HH, Reith, H, Schaefer, H.Carbamazepine therapy in epileptic patients: First results with a sustained release tablet. (Abstr.) J Neurol 1985; 232 suppl, 259.Google Scholar